Attenuation of serum inflammatory cytokines in hospitalized COVID-19 patients treated with NRICM101: A preliminary observational study.
NRICM101 administration was associated with reduced serum levels of key proinflammatory cytokines, indicating a potential anti-inflammatory effect, and may serve as an adjunctive therapy for patients with COVID-19-related hyperinflammation.